These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3286879)

  • 1. Ifosfamide.
    Zalupski M; Baker LH
    J Natl Cancer Inst; 1988 Jun; 80(8):556-66. PubMed ID: 3286879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ifosfamide--pharmacology, safety and therapeutic potential.
    Brade WP; Herdrich K; Varini M
    Cancer Treat Rev; 1985 Mar; 12(1):1-47. PubMed ID: 3896483
    [No Abstract]   [Full Text] [Related]  

  • 3. Ifosfamide vs cyclophosphamide in cancer therapy.
    Weiss RB
    Oncology (Williston Park); 1991 May; 5(5):67-76; discussion 76-82, 84-6. PubMed ID: 1653004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
    Prescrire Int; 1998 Apr; 7(34):45-7. PubMed ID: 10183382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide: European perspective.
    Burkert H
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):28-35. PubMed ID: 6761866
    [No Abstract]   [Full Text] [Related]  

  • 6. The anticancer spectrum of ifosfamide.
    Hunter HL; Harrison EF
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):96-100. PubMed ID: 6761868
    [No Abstract]   [Full Text] [Related]  

  • 7. Ifosfamide and Mesna in advanced malignancies.
    Li GC; Brock N; Li JQ; Guan ZZ; He YJ
    Chin Med J (Engl); 1988 Mar; 101(3):213-20. PubMed ID: 3136996
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Schnitker J; Brock N; Burkert H; Fichtner E
    Arzneimittelforschung; 1976; 26(10):1783-92. PubMed ID: 798586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide in the treatment of malignant epithelial ovarian tumors.
    Lissoni AA; Fei F; Rossi R; Fruscio R; Villa A; Zani G
    Oncology; 2003; 65 Suppl 2():59-62. PubMed ID: 14586150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical experience with the cytostatic drug ifosfamide].
    Ritter S; Schröder HJ
    Med Welt; 1977 Sep; 28(35):1395-1400. PubMed ID: 70737
    [No Abstract]   [Full Text] [Related]  

  • 11. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide in the treatment of soft tissue sarcomas.
    Connelly EF; Budd GT
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):16-21. PubMed ID: 8677442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
    Hoefer H; Scheef W; Titscher R; Kokron O
    Osterr Z Onkol; 1974; (1):3-7. PubMed ID: 4619650
    [No Abstract]   [Full Text] [Related]  

  • 14. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Dechant KL; Brogden RN; Pilkington T; Faulds D
    Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD006300. PubMed ID: 23235629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
    Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Verweij J; Dombernowsky P; Onsrud M; Thomas D; Sylvester R
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S180-4. PubMed ID: 8453694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
    Roguin A; Ben Arush MW; Higasi A; Kuten A
    Harefuah; 1996 Apr; 130(8):511-4, 584. PubMed ID: 8765870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    Mulder RL; Paulides M; Langer T; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2010 Feb; (2):CD006300. PubMed ID: 20166081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
    Retsas S
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():151-7. PubMed ID: 6627241
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.